Results | From 2006 to 2017, 53 903 NIH grants were awarded to first-time PIs across all 225 NIH grant types and 2766 institutions ( Table 1) . Of first-time PIs, 43.6% were female, similar to the female enrollment level of 38% in US MD-PhD programs during the same period. 5 Baseline performance measures were available for 73.4% of first-time PIs. No statistically significant differences by sex were found for baseline performance measures. The median number of articles published for men and women per year was 2.0 (P = .64), the median number of citations per article was 15 (P = .99), and the median number of research areas was 2.0 (P = .90).
For first-time PIs across all grant types and institutions, women received a median of $126 615 vs $165 721 for men (median difference, −$39 106 [95% CI, −$46 099 to −$35 675]; P < .001). For the 10 highest-funded grant types across all institutions, first-time female PIs received a median award amount of $305 823 vs $316 350 for male PIs (median difference, −$10 527 [95% CI, −$17 240 to −$3082]; P = .002), with the largest differences in N01 and U01 grants. However, women receiving R01 grants received $15 913 more than men (P < .001).
Female PIs at the Big Ten universities received a median of $66 365 vs $148 076 for male PIs (median difference, −$81 711 [95% CI, −$92 734 to −$67 450]; P < .001) ( Discussion | This study found sex differences in the size of NIH funds awarded to comparable first-time female and male PIs, even at top research institutions. Funding disparities favoring men occurred among certain grant types, although for R01 grants, the most frequent award for first-time awardees, women received larger grants, as previously observed. 6 Although the analyses controlled for key factors, limitations include possible unmeasured confounding and no data on grant applications that were turned down. Further study of the institutions where inequalities were lowest may provide insight into the reasons for sex imbalances in grant amounts awarded during formative career stages. 
COMMENT & RESPONSE Weight Loss Interventions in Adults
To the Editor The US Preventive Services Task Force (USPSTF) 1 recommended high-intensity counseling for adults with obesity, followed by regular contact for maintenance of weight loss. The task force did not issue recommendations for pharmacotherapy because of (1) perceived lack of generalizability of the clinical trial findings, owing to stringent inclusion criteria and run-in periods; (2) high rates of dropout in the trials; and (3) lack of data "about the maintenance of improvement after discontinuation of pharmacotherapy." In regard to this third point, the task force recommendation implies that medications to treat obesity should not be used on a long-term basis. However, all 4 medications approved by the US Food and Drug Administration (FDA) since 2012 for treatment of obesity have been approved for longterm use. In addition, the Endocrine Society guideline on pharmacotherapy for obesity 2 notes that medications are most appropriately used long-term. The guideline gives explicit direction for the conditions in which clinicians can use phentermine long-term (a drug that is not approved by the FDA for long-term use but is the most commonly prescribed medication in the United States for obesity). Obesity is not a lifestyle choice but rather a chronic metabolic disease. Patients with obesity experience disproportionate reductions in metabolism with even modest weight loss. They also experience increases in hunger, 3,4 which persist over time. These increases in appetite provide a rationale for the long-term use of medications to treat obesity, even so-called reduced obesity (ie, a patient whose body mass index is ≥30 but who has lost ≥5% of his or her initial weight). We believe that the task force should have addressed pharmacotherapy for obesity. In other diseases such as hypertension or type 2 diabetes, medications are given indefinitely to produce sustained improvements in blood pressure or blood glucose levels. Medications for weight reduction are similar. Although they may not be appropriate for every patient seeking treatment for their weight, they do help some individuals maintain a reduced body weight. Patients with the chronic relapsing disease of obesity deserve to be treated with the tools currently available for long-term management, which include behavioral treatment, pharmacotherapy, and, for some, bariatric surgery. (Silver Spring). 2016; 24(11):2289 -2295 . doi:10.1002 In Reply Dr Tsai and colleagues cite a guideline 1 on pharmacotherapy for obesity and state that the USPSTF should have addressed pharmacotherapy in its recommendation on adult obesity. 2 According to the authors, pharmacotherapy should be considered for long-term use because obesity is defined as a chronic disease. In reviewing the evidence, 3 the USPSTF found that participants in trials who were randomized to medications plus behavioral interventions, compared with behavioral intervention alone, were more likely to lose 5% of their weight and maintain more of their weight loss. 2 Limited data from trials also found a reduced incidence of diabetes among participants at increased risk for type 2 diabetes. Intermediate outcomes, such as use of lipid-lowering and antihypertensive medications or the prevalence of the metabolic syndrome, were rarely reported and had mixed findings. Evidence on health outcomes (eg, cancer, cardiovascular disease, mortality) was lacking. Despite some positive findings, pharmacotherapy trials had several limitations. Study participants were required to meet
